nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—CYSLTR2—respiratory system—lung cancer	0.0262	0.121	CbGeAlD
Nedocromil—FPR1—respiratory system—lung cancer	0.0235	0.109	CbGeAlD
Nedocromil—CYSLTR2—lung—lung cancer	0.0139	0.0644	CbGeAlD
Nedocromil—FPR1—bone marrow—lung cancer	0.0138	0.064	CbGeAlD
Nedocromil—PTGDR—bone marrow—lung cancer	0.013	0.0604	CbGeAlD
Nedocromil—HSP90AA1—mammary gland—lung cancer	0.0128	0.0594	CbGeAlD
Nedocromil—FPR1—lung—lung cancer	0.0125	0.058	CbGeAlD
Nedocromil—PTGDR—lung—lung cancer	0.0118	0.0547	CbGeAlD
Nedocromil—CYSLTR1—respiratory system—lung cancer	0.00984	0.0456	CbGeAlD
Nedocromil—HSP90AA1—respiratory system—lung cancer	0.00854	0.0396	CbGeAlD
Nedocromil—CYSLTR1—bronchus—lung cancer	0.0081	0.0376	CbGeAlD
Nedocromil—PTGDR—lymph node—lung cancer	0.00808	0.0374	CbGeAlD
Nedocromil—HSP90AA1—epithelium—lung cancer	0.00714	0.0331	CbGeAlD
Nedocromil—HSP90AA1—bronchus—lung cancer	0.00703	0.0326	CbGeAlD
Nedocromil—HSP90AA1—trachea—lung cancer	0.00631	0.0293	CbGeAlD
Nedocromil—HSP90AA1—cardiac atrium—lung cancer	0.00593	0.0275	CbGeAlD
Nedocromil—CYSLTR1—bone marrow—lung cancer	0.00577	0.0267	CbGeAlD
Nedocromil—CYSLTR1—lung—lung cancer	0.00523	0.0242	CbGeAlD
Nedocromil—HSP90AA1—bone marrow—lung cancer	0.00501	0.0232	CbGeAlD
Nedocromil—HSP90AA1—lung—lung cancer	0.00454	0.021	CbGeAlD
Nedocromil—CYSLTR1—lymph node—lung cancer	0.00358	0.0166	CbGeAlD
Nedocromil—HSP90AA1—lymph node—lung cancer	0.0031	0.0144	CbGeAlD
Nedocromil—Gastrointestinal disorder—Erlotinib—lung cancer	0.000762	0.00241	CcSEcCtD
Nedocromil—Fatigue—Erlotinib—lung cancer	0.000761	0.00241	CcSEcCtD
Nedocromil—Rash—Teniposide—lung cancer	0.000759	0.0024	CcSEcCtD
Nedocromil—Dermatitis—Teniposide—lung cancer	0.000758	0.0024	CcSEcCtD
Nedocromil—Sinusitis—Paclitaxel—lung cancer	0.000755	0.00239	CcSEcCtD
Nedocromil—Pain—Erlotinib—lung cancer	0.000755	0.00239	CcSEcCtD
Nedocromil—Headache—Teniposide—lung cancer	0.000754	0.00239	CcSEcCtD
Nedocromil—Gastrointestinal pain—Vinblastine—lung cancer	0.000751	0.00238	CcSEcCtD
Nedocromil—Gastrointestinal pain—Topotecan—lung cancer	0.00073	0.00231	CcSEcCtD
Nedocromil—Abdominal pain—Vinblastine—lung cancer	0.000726	0.0023	CcSEcCtD
Nedocromil—Rhinitis—Paclitaxel—lung cancer	0.000724	0.00229	CcSEcCtD
Nedocromil—Gastrointestinal pain—Erlotinib—lung cancer	0.000722	0.00229	CcSEcCtD
Nedocromil—Pharyngitis—Paclitaxel—lung cancer	0.000717	0.00227	CcSEcCtD
Nedocromil—Nausea—Teniposide—lung cancer	0.000715	0.00226	CcSEcCtD
Nedocromil—Urticaria—Topotecan—lung cancer	0.000709	0.00225	CcSEcCtD
Nedocromil—Abdominal pain—Topotecan—lung cancer	0.000705	0.00223	CcSEcCtD
Nedocromil—Body temperature increased—Topotecan—lung cancer	0.000705	0.00223	CcSEcCtD
Nedocromil—Abdominal pain—Erlotinib—lung cancer	0.000698	0.00221	CcSEcCtD
Nedocromil—Body temperature increased—Erlotinib—lung cancer	0.000698	0.00221	CcSEcCtD
Nedocromil—Visual impairment—Paclitaxel—lung cancer	0.000696	0.00221	CcSEcCtD
Nedocromil—Leukopenia—Irinotecan—lung cancer	0.00069	0.00219	CcSEcCtD
Nedocromil—Pneumonia—Docetaxel—lung cancer	0.000686	0.00217	CcSEcCtD
Nedocromil—Dyspnoea—Vinorelbine—lung cancer	0.00068	0.00216	CcSEcCtD
Nedocromil—Hypersensitivity—Vinblastine—lung cancer	0.000677	0.00214	CcSEcCtD
Nedocromil—Cough—Irinotecan—lung cancer	0.000673	0.00213	CcSEcCtD
Nedocromil—Leukopenia—Gemcitabine—lung cancer	0.000672	0.00213	CcSEcCtD
Nedocromil—Conjunctivitis—Docetaxel—lung cancer	0.000663	0.0021	CcSEcCtD
Nedocromil—Asthenia—Vinblastine—lung cancer	0.000659	0.00209	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000659	0.00209	CcSEcCtD
Nedocromil—Fatigue—Vinorelbine—lung cancer	0.000658	0.00208	CcSEcCtD
Nedocromil—Hypersensitivity—Topotecan—lung cancer	0.000657	0.00208	CcSEcCtD
Nedocromil—Tremor—Cisplatin—lung cancer	0.000656	0.00208	CcSEcCtD
Nedocromil—Cough—Gemcitabine—lung cancer	0.000656	0.00208	CcSEcCtD
Nedocromil—Pain—Vinorelbine—lung cancer	0.000653	0.00207	CcSEcCtD
Nedocromil—Asthenia—Topotecan—lung cancer	0.00064	0.00203	CcSEcCtD
Nedocromil—Chest pain—Gemcitabine—lung cancer	0.00064	0.00203	CcSEcCtD
Nedocromil—Asthenia—Erlotinib—lung cancer	0.000633	0.00201	CcSEcCtD
Nedocromil—Anaphylactic shock—Irinotecan—lung cancer	0.000629	0.00199	CcSEcCtD
Nedocromil—Diarrhoea—Vinblastine—lung cancer	0.000628	0.00199	CcSEcCtD
Nedocromil—Dysgeusia—Etoposide—lung cancer	0.000628	0.00199	CcSEcCtD
Nedocromil—Leukopenia—Cisplatin—lung cancer	0.000627	0.00199	CcSEcCtD
Nedocromil—Gastrointestinal pain—Vinorelbine—lung cancer	0.000624	0.00198	CcSEcCtD
Nedocromil—Dysgeusia—Paclitaxel—lung cancer	0.000616	0.00195	CcSEcCtD
Nedocromil—Eczema—Doxorubicin—lung cancer	0.000615	0.00195	CcSEcCtD
Nedocromil—Rhinitis—Docetaxel—lung cancer	0.000614	0.00195	CcSEcCtD
Nedocromil—Anaphylactic shock—Gemcitabine—lung cancer	0.000613	0.00194	CcSEcCtD
Nedocromil—Diarrhoea—Topotecan—lung cancer	0.00061	0.00193	CcSEcCtD
Nedocromil—Pharyngitis—Docetaxel—lung cancer	0.000608	0.00193	CcSEcCtD
Nedocromil—Dizziness—Vinblastine—lung cancer	0.000607	0.00192	CcSEcCtD
Nedocromil—Urticaria—Vinorelbine—lung cancer	0.000606	0.00192	CcSEcCtD
Nedocromil—Diarrhoea—Erlotinib—lung cancer	0.000604	0.00191	CcSEcCtD
Nedocromil—Abdominal pain—Vinorelbine—lung cancer	0.000603	0.00191	CcSEcCtD
Nedocromil—Body temperature increased—Vinorelbine—lung cancer	0.000603	0.00191	CcSEcCtD
Nedocromil—Visual impairment—Docetaxel—lung cancer	0.00059	0.00187	CcSEcCtD
Nedocromil—Dizziness—Topotecan—lung cancer	0.00059	0.00187	CcSEcCtD
Nedocromil—Tremor—Paclitaxel—lung cancer	0.000589	0.00187	CcSEcCtD
Nedocromil—Vomiting—Vinblastine—lung cancer	0.000584	0.00185	CcSEcCtD
Nedocromil—Dizziness—Erlotinib—lung cancer	0.000584	0.00185	CcSEcCtD
Nedocromil—Headache—Vinblastine—lung cancer	0.000575	0.00182	CcSEcCtD
Nedocromil—Leukopenia—Etoposide—lung cancer	0.000574	0.00182	CcSEcCtD
Nedocromil—Anaphylactic shock—Cisplatin—lung cancer	0.000571	0.00181	CcSEcCtD
Nedocromil—Vomiting—Topotecan—lung cancer	0.000567	0.0018	CcSEcCtD
Nedocromil—Leukopenia—Paclitaxel—lung cancer	0.000563	0.00178	CcSEcCtD
Nedocromil—Rash—Topotecan—lung cancer	0.000563	0.00178	CcSEcCtD
Nedocromil—Hypersensitivity—Vinorelbine—lung cancer	0.000562	0.00178	CcSEcCtD
Nedocromil—Dermatitis—Topotecan—lung cancer	0.000562	0.00178	CcSEcCtD
Nedocromil—Vomiting—Erlotinib—lung cancer	0.000561	0.00178	CcSEcCtD
Nedocromil—Dyspnoea—Irinotecan—lung cancer	0.000561	0.00178	CcSEcCtD
Nedocromil—Cough—Etoposide—lung cancer	0.00056	0.00177	CcSEcCtD
Nedocromil—Headache—Topotecan—lung cancer	0.000559	0.00177	CcSEcCtD
Nedocromil—Rash—Erlotinib—lung cancer	0.000557	0.00176	CcSEcCtD
Nedocromil—Dermatitis—Erlotinib—lung cancer	0.000556	0.00176	CcSEcCtD
Nedocromil—Dyspepsia—Irinotecan—lung cancer	0.000554	0.00176	CcSEcCtD
Nedocromil—Headache—Erlotinib—lung cancer	0.000553	0.00175	CcSEcCtD
Nedocromil—Cough—Paclitaxel—lung cancer	0.000549	0.00174	CcSEcCtD
Nedocromil—Asthenia—Vinorelbine—lung cancer	0.000548	0.00173	CcSEcCtD
Nedocromil—Dyspnoea—Gemcitabine—lung cancer	0.000547	0.00173	CcSEcCtD
Nedocromil—Chest pain—Etoposide—lung cancer	0.000546	0.00173	CcSEcCtD
Nedocromil—Eosinophilia—Methotrexate—lung cancer	0.000546	0.00173	CcSEcCtD
Nedocromil—Nausea—Vinblastine—lung cancer	0.000545	0.00173	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Irinotecan—lung cancer	0.000543	0.00172	CcSEcCtD
Nedocromil—Fatigue—Irinotecan—lung cancer	0.000543	0.00172	CcSEcCtD
Nedocromil—Pain—Irinotecan—lung cancer	0.000538	0.00171	CcSEcCtD
Nedocromil—Chest pain—Paclitaxel—lung cancer	0.000535	0.0017	CcSEcCtD
Nedocromil—Nausea—Topotecan—lung cancer	0.00053	0.00168	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000529	0.00168	CcSEcCtD
Nedocromil—Fatigue—Gemcitabine—lung cancer	0.000529	0.00167	CcSEcCtD
Nedocromil—Pain—Gemcitabine—lung cancer	0.000524	0.00166	CcSEcCtD
Nedocromil—Nausea—Erlotinib—lung cancer	0.000524	0.00166	CcSEcCtD
Nedocromil—Dry mouth—Paclitaxel—lung cancer	0.000524	0.00166	CcSEcCtD
Nedocromil—Anaphylactic shock—Etoposide—lung cancer	0.000524	0.00166	CcSEcCtD
Nedocromil—Diarrhoea—Vinorelbine—lung cancer	0.000522	0.00165	CcSEcCtD
Nedocromil—Dysgeusia—Docetaxel—lung cancer	0.000522	0.00165	CcSEcCtD
Nedocromil—Gastrointestinal pain—Irinotecan—lung cancer	0.000515	0.00163	CcSEcCtD
Nedocromil—Anaphylactic shock—Paclitaxel—lung cancer	0.000513	0.00163	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Methotrexate—lung cancer	0.000513	0.00162	CcSEcCtD
Nedocromil—Dyspnoea—Cisplatin—lung cancer	0.000509	0.00161	CcSEcCtD
Nedocromil—Dizziness—Vinorelbine—lung cancer	0.000505	0.0016	CcSEcCtD
Nedocromil—Abdominal pain—Irinotecan—lung cancer	0.000498	0.00158	CcSEcCtD
Nedocromil—Body temperature increased—Irinotecan—lung cancer	0.000498	0.00158	CcSEcCtD
Nedocromil—Pneumonia—Methotrexate—lung cancer	0.000495	0.00157	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Cisplatin—lung cancer	0.000493	0.00156	CcSEcCtD
Nedocromil—Pain—Cisplatin—lung cancer	0.000489	0.00155	CcSEcCtD
Nedocromil—Vomiting—Vinorelbine—lung cancer	0.000485	0.00154	CcSEcCtD
Nedocromil—Body temperature increased—Gemcitabine—lung cancer	0.000485	0.00154	CcSEcCtD
Nedocromil—Rash—Vinorelbine—lung cancer	0.000481	0.00152	CcSEcCtD
Nedocromil—Dermatitis—Vinorelbine—lung cancer	0.000481	0.00152	CcSEcCtD
Nedocromil—Headache—Vinorelbine—lung cancer	0.000478	0.00151	CcSEcCtD
Nedocromil—Conjunctivitis—Methotrexate—lung cancer	0.000478	0.00151	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—lung cancer	0.000478	0.00151	CcSEcCtD
Nedocromil—Leukopenia—Docetaxel—lung cancer	0.000477	0.00151	CcSEcCtD
Nedocromil—Eosinophilia—Doxorubicin—lung cancer	0.000473	0.0015	CcSEcCtD
Nedocromil—Dyspnoea—Etoposide—lung cancer	0.000467	0.00148	CcSEcCtD
Nedocromil—Cough—Docetaxel—lung cancer	0.000465	0.00147	CcSEcCtD
Nedocromil—Hypersensitivity—Irinotecan—lung cancer	0.000464	0.00147	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—lung cancer	0.000459	0.00145	CcSEcCtD
Nedocromil—Dyspnoea—Paclitaxel—lung cancer	0.000458	0.00145	CcSEcCtD
Nedocromil—Chest pain—Docetaxel—lung cancer	0.000454	0.00144	CcSEcCtD
Nedocromil—Nausea—Vinorelbine—lung cancer	0.000453	0.00144	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Etoposide—lung cancer	0.000452	0.00143	CcSEcCtD
Nedocromil—Dyspepsia—Paclitaxel—lung cancer	0.000452	0.00143	CcSEcCtD
Nedocromil—Body temperature increased—Cisplatin—lung cancer	0.000452	0.00143	CcSEcCtD
Nedocromil—Asthenia—Irinotecan—lung cancer	0.000452	0.00143	CcSEcCtD
Nedocromil—Fatigue—Etoposide—lung cancer	0.000451	0.00143	CcSEcCtD
Nedocromil—Pain—Etoposide—lung cancer	0.000448	0.00142	CcSEcCtD
Nedocromil—Dry mouth—Docetaxel—lung cancer	0.000444	0.00141	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000444	0.00141	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000443	0.0014	CcSEcCtD
Nedocromil—Fatigue—Paclitaxel—lung cancer	0.000443	0.0014	CcSEcCtD
Nedocromil—Asthenia—Gemcitabine—lung cancer	0.00044	0.00139	CcSEcCtD
Nedocromil—Pain—Paclitaxel—lung cancer	0.000439	0.00139	CcSEcCtD
Nedocromil—Pharyngitis—Methotrexate—lung cancer	0.000438	0.00139	CcSEcCtD
Nedocromil—Anaphylactic shock—Docetaxel—lung cancer	0.000435	0.00138	CcSEcCtD
Nedocromil—Diarrhoea—Irinotecan—lung cancer	0.000431	0.00136	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—lung cancer	0.000428	0.00136	CcSEcCtD
Nedocromil—Gastrointestinal pain—Etoposide—lung cancer	0.000428	0.00136	CcSEcCtD
Nedocromil—Visual impairment—Methotrexate—lung cancer	0.000425	0.00135	CcSEcCtD
Nedocromil—Hypersensitivity—Cisplatin—lung cancer	0.000421	0.00133	CcSEcCtD
Nedocromil—Gastrointestinal pain—Paclitaxel—lung cancer	0.00042	0.00133	CcSEcCtD
Nedocromil—Diarrhoea—Gemcitabine—lung cancer	0.000419	0.00133	CcSEcCtD
Nedocromil—Dizziness—Irinotecan—lung cancer	0.000416	0.00132	CcSEcCtD
Nedocromil—Urticaria—Etoposide—lung cancer	0.000416	0.00132	CcSEcCtD
Nedocromil—Abdominal pain—Etoposide—lung cancer	0.000414	0.00131	CcSEcCtD
Nedocromil—Body temperature increased—Etoposide—lung cancer	0.000414	0.00131	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—lung cancer	0.000414	0.00131	CcSEcCtD
Nedocromil—Asthenia—Cisplatin—lung cancer	0.00041	0.0013	CcSEcCtD
Nedocromil—Urticaria—Paclitaxel—lung cancer	0.000408	0.00129	CcSEcCtD
Nedocromil—Abdominal pain—Paclitaxel—lung cancer	0.000406	0.00129	CcSEcCtD
Nedocromil—Body temperature increased—Paclitaxel—lung cancer	0.000406	0.00129	CcSEcCtD
Nedocromil—Vomiting—Irinotecan—lung cancer	0.0004	0.00127	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—lung cancer	0.000399	0.00127	CcSEcCtD
Nedocromil—Rash—Irinotecan—lung cancer	0.000397	0.00126	CcSEcCtD
Nedocromil—Dermatitis—Irinotecan—lung cancer	0.000396	0.00126	CcSEcCtD
Nedocromil—Headache—Irinotecan—lung cancer	0.000394	0.00125	CcSEcCtD
Nedocromil—Diarrhoea—Cisplatin—lung cancer	0.000391	0.00124	CcSEcCtD
Nedocromil—Vomiting—Gemcitabine—lung cancer	0.00039	0.00123	CcSEcCtD
Nedocromil—Dyspnoea—Docetaxel—lung cancer	0.000388	0.00123	CcSEcCtD
Nedocromil—Rash—Gemcitabine—lung cancer	0.000387	0.00122	CcSEcCtD
Nedocromil—Dermatitis—Gemcitabine—lung cancer	0.000386	0.00122	CcSEcCtD
Nedocromil—Hypersensitivity—Etoposide—lung cancer	0.000386	0.00122	CcSEcCtD
Nedocromil—Headache—Gemcitabine—lung cancer	0.000384	0.00122	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—lung cancer	0.000383	0.00121	CcSEcCtD
Nedocromil—Dyspepsia—Docetaxel—lung cancer	0.000383	0.00121	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—lung cancer	0.000379	0.0012	CcSEcCtD
Nedocromil—Hypersensitivity—Paclitaxel—lung cancer	0.000378	0.0012	CcSEcCtD
Nedocromil—Dysgeusia—Methotrexate—lung cancer	0.000376	0.00119	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Docetaxel—lung cancer	0.000376	0.00119	CcSEcCtD
Nedocromil—Asthenia—Etoposide—lung cancer	0.000376	0.00119	CcSEcCtD
Nedocromil—Fatigue—Docetaxel—lung cancer	0.000375	0.00119	CcSEcCtD
Nedocromil—Nausea—Irinotecan—lung cancer	0.000374	0.00118	CcSEcCtD
Nedocromil—Pain—Docetaxel—lung cancer	0.000372	0.00118	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—lung cancer	0.000368	0.00117	CcSEcCtD
Nedocromil—Asthenia—Paclitaxel—lung cancer	0.000368	0.00117	CcSEcCtD
Nedocromil—Nausea—Gemcitabine—lung cancer	0.000364	0.00115	CcSEcCtD
Nedocromil—Vomiting—Cisplatin—lung cancer	0.000363	0.00115	CcSEcCtD
Nedocromil—Rash—Cisplatin—lung cancer	0.00036	0.00114	CcSEcCtD
Nedocromil—Dermatitis—Cisplatin—lung cancer	0.00036	0.00114	CcSEcCtD
Nedocromil—Diarrhoea—Etoposide—lung cancer	0.000358	0.00113	CcSEcCtD
Nedocromil—Gastrointestinal pain—Docetaxel—lung cancer	0.000356	0.00113	CcSEcCtD
Nedocromil—Diarrhoea—Paclitaxel—lung cancer	0.000351	0.00111	CcSEcCtD
Nedocromil—Dizziness—Etoposide—lung cancer	0.000346	0.0011	CcSEcCtD
Nedocromil—Abdominal pain—Docetaxel—lung cancer	0.000344	0.00109	CcSEcCtD
Nedocromil—Body temperature increased—Docetaxel—lung cancer	0.000344	0.00109	CcSEcCtD
Nedocromil—Leukopenia—Methotrexate—lung cancer	0.000344	0.00109	CcSEcCtD
Nedocromil—Dizziness—Paclitaxel—lung cancer	0.000339	0.00108	CcSEcCtD
Nedocromil—Nausea—Cisplatin—lung cancer	0.000339	0.00108	CcSEcCtD
Nedocromil—Cough—Methotrexate—lung cancer	0.000335	0.00106	CcSEcCtD
Nedocromil—Vomiting—Etoposide—lung cancer	0.000333	0.00105	CcSEcCtD
Nedocromil—Rash—Etoposide—lung cancer	0.00033	0.00105	CcSEcCtD
Nedocromil—Dermatitis—Etoposide—lung cancer	0.00033	0.00104	CcSEcCtD
Nedocromil—Headache—Etoposide—lung cancer	0.000328	0.00104	CcSEcCtD
Nedocromil—Chest pain—Methotrexate—lung cancer	0.000327	0.00104	CcSEcCtD
Nedocromil—Vomiting—Paclitaxel—lung cancer	0.000326	0.00103	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—lung cancer	0.000326	0.00103	CcSEcCtD
Nedocromil—Rash—Paclitaxel—lung cancer	0.000324	0.00103	CcSEcCtD
Nedocromil—Dermatitis—Paclitaxel—lung cancer	0.000323	0.00102	CcSEcCtD
Nedocromil—Headache—Paclitaxel—lung cancer	0.000322	0.00102	CcSEcCtD
Nedocromil—Hypersensitivity—Docetaxel—lung cancer	0.000321	0.00102	CcSEcCtD
Nedocromil—Anaphylactic shock—Methotrexate—lung cancer	0.000314	0.000993	CcSEcCtD
Nedocromil—Asthenia—Docetaxel—lung cancer	0.000312	0.000989	CcSEcCtD
Nedocromil—Nausea—Etoposide—lung cancer	0.000311	0.000985	CcSEcCtD
Nedocromil—Nausea—Paclitaxel—lung cancer	0.000305	0.000966	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—lung cancer	0.000298	0.000943	CcSEcCtD
Nedocromil—Diarrhoea—Docetaxel—lung cancer	0.000298	0.000943	CcSEcCtD
Nedocromil—Cough—Doxorubicin—lung cancer	0.00029	0.00092	CcSEcCtD
Nedocromil—Dizziness—Docetaxel—lung cancer	0.000288	0.000911	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—lung cancer	0.000283	0.000897	CcSEcCtD
Nedocromil—Dyspnoea—Methotrexate—lung cancer	0.00028	0.000886	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—lung cancer	0.000277	0.000878	CcSEcCtD
Nedocromil—Vomiting—Docetaxel—lung cancer	0.000277	0.000876	CcSEcCtD
Nedocromil—Dyspepsia—Methotrexate—lung cancer	0.000276	0.000874	CcSEcCtD
Nedocromil—Rash—Docetaxel—lung cancer	0.000274	0.000869	CcSEcCtD
Nedocromil—Dermatitis—Docetaxel—lung cancer	0.000274	0.000868	CcSEcCtD
Nedocromil—Headache—Docetaxel—lung cancer	0.000273	0.000863	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—lung cancer	0.000272	0.00086	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Methotrexate—lung cancer	0.000271	0.000858	CcSEcCtD
Nedocromil—Fatigue—Methotrexate—lung cancer	0.00027	0.000857	CcSEcCtD
Nedocromil—Pain—Methotrexate—lung cancer	0.000268	0.00085	CcSEcCtD
Nedocromil—Nausea—Docetaxel—lung cancer	0.000258	0.000819	CcSEcCtD
Nedocromil—Gastrointestinal pain—Methotrexate—lung cancer	0.000256	0.000812	CcSEcCtD
Nedocromil—Urticaria—Methotrexate—lung cancer	0.000249	0.000789	CcSEcCtD
Nedocromil—Abdominal pain—Methotrexate—lung cancer	0.000248	0.000785	CcSEcCtD
Nedocromil—Body temperature increased—Methotrexate—lung cancer	0.000248	0.000785	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—lung cancer	0.000242	0.000767	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—lung cancer	0.000239	0.000757	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000234	0.000743	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—lung cancer	0.000234	0.000742	CcSEcCtD
Nedocromil—Pain—Doxorubicin—lung cancer	0.000232	0.000736	CcSEcCtD
Nedocromil—Hypersensitivity—Methotrexate—lung cancer	0.000231	0.000732	CcSEcCtD
Nedocromil—Asthenia—Methotrexate—lung cancer	0.000225	0.000713	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—lung cancer	0.000222	0.000703	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—lung cancer	0.000216	0.000683	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—lung cancer	0.000215	0.00068	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—lung cancer	0.000215	0.00068	CcSEcCtD
Nedocromil—Diarrhoea—Methotrexate—lung cancer	0.000215	0.00068	CcSEcCtD
Nedocromil—Dizziness—Methotrexate—lung cancer	0.000207	0.000657	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—lung cancer	0.0002	0.000634	CcSEcCtD
Nedocromil—Vomiting—Methotrexate—lung cancer	0.000199	0.000632	CcSEcCtD
Nedocromil—Rash—Methotrexate—lung cancer	0.000198	0.000626	CcSEcCtD
Nedocromil—Dermatitis—Methotrexate—lung cancer	0.000198	0.000626	CcSEcCtD
Nedocromil—Headache—Methotrexate—lung cancer	0.000196	0.000622	CcSEcCtD
Nedocromil—Asthenia—Doxorubicin—lung cancer	0.000195	0.000617	CcSEcCtD
Nedocromil—Nausea—Methotrexate—lung cancer	0.000186	0.00059	CcSEcCtD
Nedocromil—Diarrhoea—Doxorubicin—lung cancer	0.000186	0.000589	CcSEcCtD
Nedocromil—Dizziness—Doxorubicin—lung cancer	0.00018	0.000569	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—lung cancer	0.000173	0.000547	CcSEcCtD
Nedocromil—Rash—Doxorubicin—lung cancer	0.000171	0.000542	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—lung cancer	0.000171	0.000542	CcSEcCtD
Nedocromil—Headache—Doxorubicin—lung cancer	0.00017	0.000539	CcSEcCtD
Nedocromil—Nausea—Doxorubicin—lung cancer	0.000161	0.000511	CcSEcCtD
Nedocromil—HSP90AA1—Metabolism—TYMS—lung cancer	5.51e-05	0.000118	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—SRC—lung cancer	5.51e-05	0.000118	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HIF1A—lung cancer	5.49e-05	0.000117	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EGFR—lung cancer	5.48e-05	0.000117	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EP300—lung cancer	5.47e-05	0.000117	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GSTM1—lung cancer	5.45e-05	0.000116	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FGFR1—lung cancer	5.43e-05	0.000116	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—PIK3CA—lung cancer	5.38e-05	0.000115	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—VEGFA—lung cancer	5.37e-05	0.000115	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STK11—lung cancer	5.36e-05	0.000114	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MDM2—lung cancer	5.36e-05	0.000114	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HIF1A—lung cancer	5.35e-05	0.000114	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—RAF1—lung cancer	5.34e-05	0.000114	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MAPK3—lung cancer	5.33e-05	0.000114	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SRC—lung cancer	5.32e-05	0.000114	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—STAT3—lung cancer	5.32e-05	0.000113	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NRAS—lung cancer	5.31e-05	0.000113	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NRAS—lung cancer	5.3e-05	0.000113	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APOA1—lung cancer	5.29e-05	0.000113	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ERBB2—lung cancer	5.28e-05	0.000113	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KIT—lung cancer	5.23e-05	0.000112	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MTOR—lung cancer	5.21e-05	0.000111	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CB—lung cancer	5.21e-05	0.000111	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—lung cancer	5.18e-05	0.000111	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MYC—lung cancer	5.18e-05	0.000111	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGF—lung cancer	5.17e-05	0.00011	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—lung cancer	5.17e-05	0.00011	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FOXO3—lung cancer	5.17e-05	0.00011	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP1A1—lung cancer	5.17e-05	0.00011	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APOA1—lung cancer	5.16e-05	0.00011	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—STAT3—lung cancer	5.13e-05	0.00011	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ERCC2—lung cancer	5.12e-05	0.000109	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NRAS—lung cancer	5.12e-05	0.000109	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KDR—lung cancer	5.12e-05	0.000109	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—MAPK3—lung cancer	5.08e-05	0.000109	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MAPK3—lung cancer	5.08e-05	0.000108	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—lung cancer	5.01e-05	0.000107	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—lung cancer	4.98e-05	0.000106	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—lung cancer	4.94e-05	0.000105	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MAPK3—lung cancer	4.9e-05	0.000105	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CASP8—lung cancer	4.88e-05	0.000104	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6R—lung cancer	4.86e-05	0.000104	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CREBBP—lung cancer	4.85e-05	0.000104	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AVP—lung cancer	4.85e-05	0.000103	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—lung cancer	4.84e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—lung cancer	4.84e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KIT—lung cancer	4.83e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APC—lung cancer	4.83e-05	0.000103	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—lung cancer	4.83e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—lung cancer	4.82e-05	0.000103	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—lung cancer	4.79e-05	0.000102	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL2—lung cancer	4.79e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGF—lung cancer	4.78e-05	0.000102	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—lung cancer	4.77e-05	0.000102	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—lung cancer	4.76e-05	0.000102	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APC—lung cancer	4.72e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CG—lung cancer	4.72e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KIT—lung cancer	4.72e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—NRAS—lung cancer	4.71e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—lung cancer	4.67e-05	9.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1R—lung cancer	4.67e-05	9.96e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—lung cancer	4.67e-05	9.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGF—lung cancer	4.66e-05	9.95e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—JUN—lung cancer	4.66e-05	9.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAP2K1—lung cancer	4.63e-05	9.89e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CD—lung cancer	4.6e-05	9.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HES1—lung cancer	4.58e-05	9.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—lung cancer	4.57e-05	9.75e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—lung cancer	4.56e-05	9.74e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—BRAF—lung cancer	4.54e-05	9.69e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—lung cancer	4.53e-05	9.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MAPK3—lung cancer	4.52e-05	9.64e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1A—lung cancer	4.51e-05	9.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—lung cancer	4.5e-05	9.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—POMC—lung cancer	4.49e-05	9.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6R—lung cancer	4.49e-05	9.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CREBBP—lung cancer	4.48e-05	9.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—APOA1—lung cancer	4.43e-05	9.46e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—BRAF—lung cancer	4.43e-05	9.46e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—lung cancer	4.41e-05	9.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—lung cancer	4.4e-05	9.38e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—lung cancer	4.39e-05	9.38e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6R—lung cancer	4.38e-05	9.34e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CREBBP—lung cancer	4.37e-05	9.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—lung cancer	4.3e-05	9.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EP300—lung cancer	4.3e-05	9.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAP2K1—lung cancer	4.28e-05	9.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—lung cancer	4.26e-05	9.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CD—lung cancer	4.25e-05	9.07e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—lung cancer	4.21e-05	8.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—lung cancer	4.2e-05	8.96e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—lung cancer	4.19e-05	8.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB3—lung cancer	4.19e-05	8.94e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SRC—lung cancer	4.18e-05	8.91e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAP2K1—lung cancer	4.17e-05	8.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CD—lung cancer	4.14e-05	8.85e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MDM2—lung cancer	4.12e-05	8.8e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—RAF1—lung cancer	4.11e-05	8.77e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—lung cancer	4.11e-05	8.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—lung cancer	4.07e-05	8.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERBB2—lung cancer	4.06e-05	8.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—lung cancer	4.06e-05	8.66e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—lung cancer	4.06e-05	8.66e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—lung cancer	4.05e-05	8.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CG—lung cancer	4.05e-05	8.64e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—lung cancer	4.03e-05	8.6e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NRAS—lung cancer	4.02e-05	8.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—lung cancer	4.02e-05	8.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MTOR—lung cancer	4.01e-05	8.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CB—lung cancer	4.01e-05	8.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD4—lung cancer	4e-05	8.54e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—lung cancer	3.92e-05	8.36e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGFR1—lung cancer	3.9e-05	8.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—lung cancer	3.88e-05	8.29e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—lung cancer	3.88e-05	8.29e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—lung cancer	3.88e-05	8.28e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—POMC—lung cancer	3.85e-05	8.22e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK3—lung cancer	3.85e-05	8.21e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HIF1A—lung cancer	3.84e-05	8.2e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MDM2—lung cancer	3.81e-05	8.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—RAF1—lung cancer	3.79e-05	8.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CREBBP—lung cancer	3.75e-05	8.01e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERBB2—lung cancer	3.75e-05	8.01e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—lung cancer	3.75e-05	7.99e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—lung cancer	3.74e-05	7.99e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—lung cancer	3.73e-05	7.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—lung cancer	3.72e-05	7.93e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MDM2—lung cancer	3.71e-05	7.92e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—lung cancer	3.71e-05	7.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APOA1—lung cancer	3.71e-05	7.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MTOR—lung cancer	3.7e-05	7.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CB—lung cancer	3.7e-05	7.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—RAF1—lung cancer	3.7e-05	7.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD4—lung cancer	3.7e-05	7.89e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL2—lung cancer	3.68e-05	7.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KDR—lung cancer	3.67e-05	7.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—lung cancer	3.67e-05	7.83e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ERBB2—lung cancer	3.66e-05	7.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—lung cancer	3.66e-05	7.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MTOR—lung cancer	3.61e-05	7.71e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CB—lung cancer	3.61e-05	7.71e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—lung cancer	3.59e-05	7.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—JUN—lung cancer	3.58e-05	7.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CD—lung cancer	3.56e-05	7.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ALB—lung cancer	3.51e-05	7.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1A—lung cancer	3.47e-05	7.41e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—lung cancer	3.47e-05	7.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—lung cancer	3.47e-05	7.4e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—lung cancer	3.46e-05	7.38e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—lung cancer	3.45e-05	7.36e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—lung cancer	3.43e-05	7.32e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—lung cancer	3.43e-05	7.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CG—lung cancer	3.38e-05	7.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KIT—lung cancer	3.38e-05	7.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APC—lung cancer	3.38e-05	7.22e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—lung cancer	3.35e-05	7.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGF—lung cancer	3.35e-05	7.14e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—lung cancer	3.32e-05	7.09e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL2—lung cancer	3.32e-05	7.08e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—lung cancer	3.31e-05	7.06e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EP300—lung cancer	3.31e-05	7.05e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—lung cancer	3.3e-05	7.05e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—lung cancer	3.23e-05	6.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—JUN—lung cancer	3.23e-05	6.89e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—POMC—lung cancer	3.22e-05	6.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SRC—lung cancer	3.21e-05	6.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1A—lung cancer	3.21e-05	6.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—lung cancer	3.2e-05	6.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—BRAF—lung cancer	3.18e-05	6.79e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—lung cancer	3.18e-05	6.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6R—lung cancer	3.14e-05	6.71e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—lung cancer	3.14e-05	6.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CREBBP—lung cancer	3.14e-05	6.7e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1A—lung cancer	3.13e-05	6.68e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—lung cancer	3.12e-05	6.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CB—lung cancer	3.1e-05	6.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—lung cancer	3.1e-05	6.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NRAS—lung cancer	3.09e-05	6.6e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—lung cancer	3.07e-05	6.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—lung cancer	3.07e-05	6.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EP300—lung cancer	3.05e-05	6.51e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—lung cancer	3.05e-05	6.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAP2K1—lung cancer	2.99e-05	6.39e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EP300—lung cancer	2.98e-05	6.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CD—lung cancer	2.98e-05	6.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SRC—lung cancer	2.97e-05	6.33e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK3—lung cancer	2.96e-05	6.32e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—lung cancer	2.94e-05	6.27e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SRC—lung cancer	2.9e-05	6.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—lung cancer	2.86e-05	6.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NRAS—lung cancer	2.85e-05	6.09e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—lung cancer	2.82e-05	6.02e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—lung cancer	2.82e-05	6.01e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—lung cancer	2.81e-05	6e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—lung cancer	2.79e-05	5.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NRAS—lung cancer	2.79e-05	5.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAPK3—lung cancer	2.73e-05	5.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—lung cancer	2.68e-05	5.72e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK3—lung cancer	2.67e-05	5.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MDM2—lung cancer	2.67e-05	5.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—lung cancer	2.66e-05	5.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—lung cancer	2.66e-05	5.67e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RAF1—lung cancer	2.66e-05	5.67e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB2—lung cancer	2.63e-05	5.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—lung cancer	2.6e-05	5.55e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—lung cancer	2.6e-05	5.54e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—lung cancer	2.59e-05	5.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MTOR—lung cancer	2.59e-05	5.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CB—lung cancer	2.59e-05	5.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—EP300—lung cancer	2.56e-05	5.45e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—lung cancer	2.54e-05	5.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—lung cancer	2.49e-05	5.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—lung cancer	2.46e-05	5.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—lung cancer	2.45e-05	5.22e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—lung cancer	2.4e-05	5.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—lung cancer	2.39e-05	5.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2—lung cancer	2.38e-05	5.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—lung cancer	2.32e-05	4.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JUN—lung cancer	2.32e-05	4.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—lung cancer	2.26e-05	4.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—lung cancer	2.26e-05	4.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—lung cancer	2.25e-05	4.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1A—lung cancer	2.25e-05	4.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—lung cancer	2.24e-05	4.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—lung cancer	2.2e-05	4.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—lung cancer	2.17e-05	4.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EP300—lung cancer	2.14e-05	4.56e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—lung cancer	2.13e-05	4.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—lung cancer	2.09e-05	4.46e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SRC—lung cancer	2.08e-05	4.43e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—lung cancer	2.04e-05	4.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—lung cancer	2.02e-05	4.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—lung cancer	2e-05	4.28e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRAS—lung cancer	2e-05	4.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—lung cancer	2e-05	4.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—lung cancer	2e-05	4.26e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—lung cancer	1.95e-05	4.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK3—lung cancer	1.91e-05	4.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—lung cancer	1.89e-05	4.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—lung cancer	1.86e-05	3.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—lung cancer	1.84e-05	3.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—lung cancer	1.82e-05	3.89e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—lung cancer	1.8e-05	3.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—lung cancer	1.72e-05	3.67e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—lung cancer	1.58e-05	3.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—lung cancer	1.54e-05	3.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—lung cancer	1.53e-05	3.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—lung cancer	1.46e-05	3.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—lung cancer	1.4e-05	2.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—lung cancer	1.29e-05	2.76e-05	CbGpPWpGaD
